Vai al contenuto principale
Logo Università
Logo di Farmacia - Chimica e tecnologia farmaceutiche

Dipartimento di Scienza e Tecnologia del Farmaco

Farmacia - Chimica e tecnologia farmaceutiche

Seguici su

Logo di Farmacia - Chimica e tecnologia farmaceutiche

Maria Teresa Fierro

Professore/Professoressa associato/a

Contatti

Presso

  • Farmacia - Chimica e tecnologia farmaceutiche
  • Laurea Magistrale in Medicina e Chirurgia - sede di Torino

Curriculum vitae

  • Curriculum Vitae (34.2 KB)

    • Insegnamenti

    Temi di ricerca

    Prof.ssa Maria Teresa Fierro

      ELENCO DELLE PUBBLICAZIONI

    1. Foa R, Catovsky D, Incarbone E, Cherchi M, Wechsler A, Lusso P, Fierro MT, Giubellino MC, Bernengo MG, Semenzato G. Chronic T-cell leukaemias. III. T-colonies, PHA response and correlation with membrane phenotype. Leuk Res. 1982;6(6):809-14.
    2. Fierro MT, Giubellino MC, Lusso P, Ferrando ML, Foa R. [OK T-positivity in stimulated T-lymphocytes]. Boll Soc Ital Biol Sper. 1982 Mar 30;58(6):311-4. 
    3. Lusso P, Giubellino MC, Fierro MT, Ferrando ML, Pio C, Foa R. [Effect of human plasma on the in vitro formation of T-lymphocyte colonies]. Boll Soc Ital Biol Sper. 1982 Mar 30;58(6):306-10.
    4. Foa R, Caligaris Cappio F, Campana D, Fierro MT, Bergui L, Giubellino MC, Lusso P. Relevance of monoclonal antibodies in the diagnosis of unusual T-cell acute lymphoblastic leukaemia. Scand J Haematol. 1983 Apr;30(4):303-7.
    5. Lauria F, Foa R, Mantovani V, Fierro MT, Catovsky D, Tura S. T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the T-helper subset. Br J Haematol. 1983 Jun;54(2):277-83.
    6. Foa R, Lauria F, Raspadori D, Lusso P, Ferrando ML, Fierro MT, Giubellino MC, Catovsky D.Normal helper T-cell function in hairy-cell leukaemia. Scand J Haematol. 1983 Oct;31(4):322-8. 
    7. Caligaris-Cappio F, Gobbi M, Bergui L, Campana D, Lauria F, Fierro MT, Foa R. B-chronic lymphocytic leukaemia patients with stable benign disease show a distinctive membrane phenotype. Br J Haematol. 1984 Apr;56(4):655-60.
    8. Foa R, Lusso P, Fierro MT, Giubellino MC, Ferrando ML, Pegoraro L. Effects of 12-o-tetradecanoyl-phorbol-13-acetate (TPA) on the colony growth of human T lymphocytes. Clin Exp Immunol. 1984 May;56(2):377-82.
    9. Foa R, Lauria F, Lusso P, Giubellino MC, Fierro MT, Ferrando ML, Raspadori D, Matera L. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1984 Nov;58(3):509-16.
    10. Foa R, Giubellino MC, Fierro MT, Lusso P, Ferrando ML. Immature T lymphocytes in human cord blood identified by monoclonal antibodies: a model for the study of the differentiation pathway of T cells in humans. Cell Immunol. 1984 Nov;89(1):194-201. 
    11. Foa R, Migone N, Saitta M, Fierro MT, Giubellino MC, Lusso P, Cordero di Montezemolo L, Miniero R, Lauria F. Different stages of B cell differentiation in non-T acute lymphoblastic leukemia. J Clin Invest. 1984 Nov;74(5):1756-63.
    12. Pegoraro L, Fierro MT, Lusso P, Giovinazzo B, Lanino E, Giovarelli M, Matera L, Foa R. A novel leukemia T-cell line (PF-382) with phenotypic and functional features of suppressor lymphocytes. J Natl Cancer Inst. 1985 Aug;75(2):285-90.
    13. Foa R, Giovarelli M, Jemma C, Fierro MT, Lusso P, Ferrando ML, Lauria F, Forni G. Interleukin 2 (IL 2) and interferon-gamma production by T lymphocytes from patients with B-chronic lymphocytic leukemia: evidence that normally released IL 2 is absorbed by the neoplastic B cell population. Blood. 1985 Sep;66(3):614-9.
    14. Foa R, Fierro MT, Lusso P, Raspadori D, Ferrando ML, Matera L, Malavasi F, Lauria F. Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28. Br J Haematol. 1986 Jan;62(1):151-4.
    15. Lauria F, Raspadori D, Foa R, Tazzari PL, Lusso P, Fierro MT, Matera L, Baccarani M, Tura S. Normal T-lymphocyte function in patients with Hodgkin's disease in long-lasting remission. Tumori. 1986 Feb 28;72(1):75-80.
    16. Foa R, Lauria F, Lusso P, Raspadori D, Fierro MT, Tazzari PL, Caudana L, Matera L. Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia. Clin Exp Immunol. 1986 May;64(2):392-8.
    17. Foa R, Fierro MT, Giovarelli M, Lusso P, Benetton G, Bonferroni M, Forni G. Immunoregulatory T-cell defects in B-cell chronic lymphocytic leukemia: cause or consequence of the disease? The contributory role of decreased availability of interleukin 2 (IL-2). Blood Cells. 1987;12(2):399-412.
    18. Foa R, Fierro MT, Lusso P, Bonferroni M, Raspadori D, Buzzi M, Zinzani PL, Resegotti L, Lauria F. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia. Leukemia. 1987 Apr;1(4):377-9.
    19. Guerrasio A, Avanzi GC, Pegoraro L, Estivill X, Serra A, Giubellino MC, Fierro MT, Novarino A, Foa R, Saglio G. Rearrangement of the c-myc oncogene with heavy-chain immunoglobulin enhancer in tumor DNA from an acute lymphoblastic leukemia patient. J Natl Cancer Inst. 1987 May;78(5):845-51.
    20. Lauria F, Foa R, Raspadori D, Tazzari PL, Migone N, Giubellino MC, Lusso P, Fierro MT, Motta MR, Tassinari A, et al. Chronic T-cell leukaemias. A variant of T-prolymphocytic leukaemias: morphological, immunological and clinical characterization of 2 cases. Eur J Haematol. 1987 Jul;39(1):1-6.
    21. Bellone G, Foa R, Fierro MT, Avanzi GC, Lusso P, Ramello A, Lista P, Ghio R, Pegoraro L. A human leukemic T cell line (PF-382) inhibits the growth of myeloid and erythroid progenitor cells. Leukemia. 1987 Aug;1(8):603-8.
    22. Foa R, Migone N, Fierro MT, Basso G, Lusso P, Putti MC, Giubellino MC, Saitta M, Miniero R, Casorati G, et al. Genotypic characterization of common acute lymphoblastic leukemia may improve the phenotypic classification. Exp Hematol. 1987 Oct;15(9):942-5.
    23. Morabito F, Tassinari A, Callea V, Brugiatelli M, Fierro MT, Saglio G, Neri A, Foa R.  Germ-line configuration of the T-cell receptor beta-chain gene in B-cell chronic lymphoproliferative disorders which co-express T-cell antigens. Eur J Haematol. 1987. Nov;39(5):412-7.
    24. Foa R, Giovarelli M, Fierro MT, Bonferroni M, Forni G. Autocrine or paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia. Nouv Rev Fr Hematol. 1988;30(5-6):339-41. Review.
    25. Fierro MT, Liao XS, Lusso P, Bonferroni M, Matera L, Cesano A, Lista P, Arione R, Forni G, Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia. 1988 Jan;2(1):50-4.
    26. Giovarelli M, Foa R, Benetton G, Lusso P, Fierro MT, Forni G. Release of interleukin-2-like material by B-chronic lymphocytic leukemia cells. An autocrine or paracrine model of production and utilization? Leuk Res. 1988;12(3):201-9.  
    27. Callea V, Morabito F, Lista P, Pegoraro L, Cambrin GR, Guerrasio A, Saglio G, Tassinari A, Fierro MT, Iacopino P, et al. Multilineage cell involvement in Ph1-negative, bcr-negative chronic myeloid leukemia. Leuk Res. 1988;12(8):637-45.
    28. Lauria F, Foa R, Raspadori D, Zinzani PL, Buzzi M, Fierro MT, Bonferroni M, Fanin R, Gallizia C, Michieli MG, et al. Treatment of hairy-cell leukaemia with alpha-interferon (alpha-IFN). Eur J Cancer Clin Oncol. 1988 Feb;24(2):195-200. 
    29. Paciucci PA, Chesa PG, Fierro MT, Gordon R, Konefal RG, Glidewell O, Holland JF. Pinocchio cells: morphologically atypical immunologically heterogeneous lymphocytes induced by  treatment with interleukin 2. Immunol Lett. 1988 Dec;19(4):313-20.
    30. Foa R, Fierro MT, Raspadori D, Bonferroni M, Cardona S, Liao XS, Cesano A, Matera L, Gillio Tos A, Tola E, et al. Lymphokine activated killer (LAK) activity in lymphoproliferative disorders. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:153-5. Review.
    31. Foa R, Migone N, Francia di Celle P, Fierro MT, Tassinari A, Lo Coco F, Casorati G, Gavosto F. Ontogeny, gene rearrangements and immunophenotype of acute leukaemias. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:66-9. Review.
    32. Lista P, Fierro MT, Liao XS, Bonferroni M, Brizzi MF, Porcu P, Pegoraro L, Foa R. Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells. Eur J Haematol. 1989 May;42(5):425-30. 
    33. Brugiatelli M, Callea V, Morabito F, Oliva B, Francia Di Celle P, Fierro MT, Neri A, Foa R. Immunologic and molecular evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical remission phase. Cancer. 1989 May 15;63(10):1979-84.
    34. Foa R, Caretto P, Fierro MT, Bonferroni M, Cardona S, Guarini A, Lista P, Pegoraro L, Mandelli F, Forni G, et al. Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin. Br J Haematol. 1990 May;75(1):34-40.
    35. Foa R, Massaia M, Cardona S, Tos AG, Bianchi A, Attisano C, Guarini A, di Celle PF, Fierro MT. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood. 1990 Jul 15;76(2):393-400.
    36. Foa R, Fierro MT, Raspadori D, Bonferroni M, Cardona S, Guarini A, Tos AG, di Celle PF, Cesano A, Matera L. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors. Blood. 1990 Oct 1;76(7):1349-54.
    37. Foa R, Guarini A, Gillio Tos A, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F. Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation. Cancer Res. 1991 Feb 1;51(3):964-8.  
    38. Foa R, Fierro MT, Cesano A, Guarini A, Bonferroni M, Raspadori D, Miniero R, Lauria F, Gavosto F. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood. 1991 Aug 15;78(4):1041-6.
    39. Fierro MT, Lisa F, Novelli M, Bertero M, Bernengo MG. Soluble interleukin-2 receptor, CD4 and CD8 levels in melanoma: a longitudinal study. Dermatology. 1992;184(3):182-9.
    40. Savoia P, Novelli M, Fierro MT, Cremona O, Marchisio PC, Bernengo MG. Expression and role of integrin receptors in Sezary syndrome. J Invest Dermatol. 1992 Aug;99(2):151-9.
    41. Bernengo MG, Appino A, Bertero M, Novelli M, Fierro MT, Doveil GC, Lisa F. Thymopentin in Sezary syndrome. J Natl Cancer Inst. 1992 Sep 2;84(17):1341-6. 
    42. Bernengo MG, Fierro MT, Novelli M, Lisa F, Appino A. Soluble interleukin-2 receptor in Sezary syndrome: its origin and clinical application. Br J Dermatol. 1993 Feb;128(2):124-9.
    43. Fierro MT, Bertero M, Novelli M, Appino A, Doveil GC, Colonna S, Bernengo MG. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Melanoma Res. 1993 Apr;3(2):127-31.
    44. Bertero M, Novelli M, Fierro MT, Bernengo MG. Mantle zone lymphoma: an immunohistologic study of skin lesions. J Am Acad Dermatol. 1994 Jan;30(1):23-30.
    45. Doveil GC, Fierro MT, Novelli M, Appino A, Bertero M, Quaglino P, Bernengo MG. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance. Dermatology. 1995;191(3):234-9.
    46. Novelli M, Savoia P, Fierro MT, Verrone A, Quaglino P, Bernengo MG. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol. 1996 Jun;134(6):1052-6.
    47. Guarini A, Gansbacher B, Cronin K, Fierro MT, Foa R. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response. Cytokines Mol Ther. 1995;1(1):57-64. 
    48. Bernengo MG, Doveil GC, Bertero M, Quaglino P, Fierro MT, Savoia P, Appino A, Colonna S. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma a pilot study. Melanoma Res. 1996 Jun;6(3):257-65.
    49. Fierro MT, Doveil GC, Quaglino P, Savoia P, Verrone A, Bernengo MG. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (VICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology. 1997;194(3):268-72.
    50. Savoia P, Fierro MT, Novelli M, Quaglino P, Verrone A, Geuna M, Bernengo MG. CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol. 1997;137(6):966-71.
    51. Tomasini C, Quaglino P, Novelli M, Fierro MT. "Aleukemic" granulomatous leukemia cutis. Am J Dermatopathol. 1998 Aug;20(4):417-21. 
    52. Bernengo MG, Quaglino P, Novelli M, Cappello N, Doveil GC, Lisa F, De Matteis A, Fierro MT, Appino A. Prognostic factors in Sezary syndrome: a multivariate analysis of clinical, haematological and immunological features. Ann Oncol. 1998;9(8):857-63.
    53. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma. 1998 Nov;31(5-6):583-8.
    54. Bernengo MG, Quaglino P, Cappello N, Lisa F, Osella-Abate S, Fierro MT. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. Melanoma Res. 2000 Feb;10(1):55-65.
    55. Savoia P, Fierro MT, Zaccagna A, Bernengo MG. Metastatic melanoma of the heart. J Surg Oncol. 2000 Nov;75(3):203-7.
    56. Bernengo MG, Novelli M, Quaglino P, Lisa F, De Matteis A, Savoia P, Cappello N, Fierro MT. The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells. Br J Dermatol. 2001;144(1):125-35.
    57. Fierro MT, Novelli M, Savoia P, Cambieri I, Quaglino P, Osella-Abate S, Bernengo MG. CD45RA+ immunophenotype in mycosis fungoides: clinical, histological and immunophenotypical features in 22 patients. J Cutan Pathol. 2001;28(7):356-62.
    58. Quaglino P, Novelli M, Fierro MT. Evoluzione da linfoma a grandi cellule anaplastiche CD30-positive a papulosi linfomatoide tipo A: presentazione di un caso. Dermatol. Clin. 2002; 22(3-4): 107-109.
    59. Novelli M, Comessati A, Quaglino P, Savoia P, Fierro MT, Bernengo MG: CD26 expression on cutaneous infiltrates from patients with cutaneous T-cell lymphoma (CTCL) CD26 in cutaneous T-cell lymphoma patients. Adv Exp Med Biol 524:223-34, 2003.
    60. Fierro MT, Savoia P, Quaglino P, Novelli M, Barberis M, Bernengo MG: Systemic therapy with cyclophosphamide and anti-CD20 antibody (Rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of seven cases.J Am Acad Dermatol, 2003 Aug;49(2):281-7.
    61. Osella-Abate S, Savoia P, Quaglino P, Fierro MT, Leporati C, Ortoncelli M, Bernengo MG: Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated to a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer, 2003; 89 (8): 1457-62.
    62. Quaglino P, Savoia P, Fierro MT, Osella-Abate S, Bernengo MG: Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Melanoma Res, Melanoma Res. 2004 Apr;14(2):S17-9.
    63. Quaglino P, Fierro MT, Rossotto G, Savoia P, Bernengo MG: Treatment of advanced mycosis fungoides/Sezary syndrome with fludarabine and potential adjuntive benefit to subsequent extracorporeal photochemotherapy. Br J Dermatol. 2004 Feb;150(2):327-36.
    64. Macripo G, Quaglino P, Caliendo V, Ronco AM, Soltani S, Giacone E, Pau S, Fierro MT, Bernengo MG. Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study. Melanoma Res. 2004 Apr;14(2):S9-12.
    65. Fierro MT, Savoia P, Quaglino P, Novero D, Bernengo MG.Disseminated Kaposi's sarcoma associated with idiopathic CD4+ lymphocytopenia and low dose  steroid therapy. Clin Exp Dermatol. 2005 Jul;30(4):395-7.
    66. Ponti R, Quaglino P, Novelli M, Fierro MT, Comessatti A, Peroni A, Bonello L, Bernengo MG.  T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.Br J Dermatol. 2005 Sep;153(3):565-73.
    67. Bernengo MG, Quaglino P, Cappello N, Fierro MT, DOveil GC, Macripò G, Osella-Abate S, Peroni A, Lisa F, Savoia P. Time course and pattern of relapse in stage I-II primary cutaneous melanoma: a multivariate analysis of disease-free survival in 3174 patients followed-up at the Turin Melanoma Centre from 1975 to 2004. G It Dermatol Venereol 2005; 140: 191-200.
    68. Quaglino P, Osella-Abate S, Savoia P, Fierro MT, Bernengo MG. Immunobiology of melanoma: the dark side of the moon? Rec Res Devel Resp Critical Care Med 2005; 3: 21-36.
    69. Fierro MT, Comessatti A, Quaglino P, Ortoncelli M, Osella Abate S, Ponti R, Novelli M, Bernengo MG. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sezary syndrome. Dermatology 2006;213(4):284-92.
    70. Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, Fierro MT. Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784-94.
    71. Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardo T, Fierro MT, Cavallo F, Savoia P, Bernengo MG. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res. 2007; 17(2):75-82.
    72. Savoia P, Ortoncelli M, Osella-Abate S, Quaglino P, Mola F, Fierro MT, Bernengo MG.  Melanoma and pregnancy: a 30-year experience at the Turin melanoma centre and a review of the literature data. G Ital Dermatol Venereol 2007; 142:1-7.
    73. Ponti R, Bergallo M, Costa C, Quaglino P, Fierro MT, Comessatti A, Stroppiana E, Sidoti F, Merlino C, Novelli M, Alotto D, Cavallo R, Bernengo MG. Human herpesvirus 7 detection by quantitative real time polymerase chain reaction in primary cutaneous T-cell lymphomas and healthy subjects: lack of a pathogenic role. Br J Dermatol. 2008 Sep 6. [Epub ahead of print]
    74. Novelli M, Fierro MT, Quaglino P, Comessatti A, Lisa F, Ponti R, Savoia P, Bernengo MG. Flow cytometry immunophenotyping in mycosis fungoides. J Am Acad Dermatol. 2008 Sep;59(3):533-4.
    75. Fierro MT, Novelli M, Quaglino P, Comessatti A, Fava P, Ortoncelli M, Ponti R, Bernengo MG. Heterogeneity of circulating CD4+ memory T-cell subsets in erythrodermic patients: CD27 analysis can help to distinguish cutaneous T-cell lymphomas from inflammatory erythroderma. Dermatology. 2008;216(3):213-21.
    76. Ponti R, Fierro MT, Quaglino P, Lisa B, Paola FC, Michela O, Paolo F, Comessatti A, Novelli M, Bernengo MG. TCRgamma-chain gene rearrangement by PCR-based GeneScan: diagnostic accuracy improvement and clonal heterogeneity analysis in multiple cutaneous T-cell lymphoma samples. J Invest Dermatol. 2008 Apr;128(4):1030-8.
    77. Novelli M,  Merlino C, Ponti R, Bergallo M,  Quaglino P, Cambieri I, Comessatti A, Sidoti F, Costa C,  Corino D, Cavallo R, Negro Ponzi A, Fierro MT, Bernengo MG. Epstein-Barr Virus in cutaneous T-Cell Lymphomas: evaluation of the viral presence and significance in skin and peripheral blood. J Invest. 2008 (in press)

     

    Gruppi di ricerca

    Dermatologia e Venereologia

    Ricerca Traslazionale sul Melanoma

    Gruppi di ricerca

    Attività in agenda

    Consulta la mia agenda

    Ricevimento studenti

    Ricevimento studenti: da concordare previo contatto telefonico al 011-6335857

    Ultimo aggiornamento: 08/05/2023 09:35

    Location: https://www.farmacia-dstf.unito.it/robots.html
    Non cliccare qui!